期刊文献+

辛伐他汀加阿司匹林预防脑梗死复发的疗效观察

暂未订购
导出
摘要 目的探讨辛伐他汀加阿司匹林预防脑梗死复发的疗效。方法选择2003年1月至2005年1月我院收治的脑梗死患者172例,观察组82例,应用辛伐他汀20 mg,每晚1次口服;肠溶阿司匹林100 mg/d,顿服。对照组90例,应用肠溶阿司匹林100 mg/d,顿服。观察两组治疗1年内缺血性卒中的发生率,并于治疗前和治疗后分别检测两组血清C-反应蛋白(CRP)、总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)和低密度脂蛋白胆固醇(LDL-C)的变化。结果观察组1年内脑梗死再发率(6.1%)与对照组(25.6%)相比,差异有统计学意义(P〈0.05)。观察组血清CRP、TC、TG和LDL-C水平治疗后均下降,HDL-C水平升高,与治疗前相比,差异有统计学意义(P〈0.05)。结论辛伐他汀与阿司匹林联用,对预防缺血性卒中复发效果优于单用阿司匹林。
出处 《中原医刊》 2007年第12期77-78,共2页 Central Plains Medical Journal
  • 相关文献

参考文献6

  • 1郭毅,周志斌,姜昕,赵宏文,陈实,古坤毅,马可夫.急性脑梗死患者颈动脉斑块与血清C反应蛋白及白细胞计数的关系[J].临床神经病学杂志,2003,16(5):266-268. 被引量:137
  • 2高建国,周农,翟金霞.血清C反应蛋白水平与脑梗死预后的关系[J].临床神经病学杂志,2005,18(1):43-44. 被引量:112
  • 3Sever PS, Dahlof B, Poulter MR, et al. Prevention of coronary and stroke events with atovvastatin in hypertenswe patients who have average or lower than average cholesterol concentrations, in the Anglo Scandinavian Cardiac Outcomes Trial Lipid Lowering Ann ( ASCOT LLA ) : a multicentre randomized controlled trial. Lancet ,2003,361 (9364) : 1149 - 1158.
  • 4张大庆,赵水平.他汀类药物对脑卒中的防治评价[J].中国动脉硬化杂志,2001,9(3):272-274. 被引量:2
  • 5Heart Protection Study, Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,563 high risk individuals: a randomised placebo cotrolld trial. Curr Cardio Rep, 2002,4 (6) :486 -487.
  • 6Byington RP,Jukema JW,Salonen JT,et al. Reduction in cardiovascular events during pravastatin therapy: pooled analysis of clinical events of the pravastatin atherosclerosis intervention program. Circulation,1995,92:2419.

二级参考文献38

  • 1脑卒中患者临床神经功能缺损程度评分标准(1995)[J].中华神经科杂志,1996,29(6):381-383. 被引量:15807
  • 2[1]Gorelick PB,Sacco RL,Ssmith DB, et al. Prevention of a first stroke, A review of guidelines and a multidisciplinary consensus statement from the National Stroke Association [J]. JAMA, 1999, 281:1 112-120
  • 3[2]Prospective Studies Collaboration. Cholesterol, diastolic blood pressure, and stroke: 13 000 strokes in 450 000 people in 45 prospective cohort [J]. Lancet, 1995, 346: 1 647-653
  • 4[3]Neaton JD, Blackbum H,Jacobs D, et al. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial [J]. Arch Intern Med, 1992, 152: 1 490-500
  • 5[4]Eastern Stroke, Coronary Heart Disease Collaborative Research Group. Blood pressure, cholestorl,and stroke in eastern Asia [J]. Lancet, 1998, 352: 1 801-807
  • 6[5]Lindenstrom E,Boysen G,Nyboe J. Influence of total cholesterol,high density lipoprotin cholesterol, and triglycerides on risk of cerebrovascular disease:the Copenhagen city heart study [J]. BMJ, 1994, 309: 11-15
  • 7[6]Benfante R, Yano K, Hwang LJ, et al. Elevated serum cholesterol is a risk factor for both coronary heart disease and thromboembolic stroke in Hawaiian Japanese men [J]. Stroke, 1994, 25: 814-820
  • 8[7]Blauw Gj, Lagaay AM, Smelt AH, et al. Stroke,statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials wiyh HMG-CoA reductase inhibitors [J]. Stroke, 1997, 28: 946-950
  • 9[8]Bucher HC, Griffith LE, Guyatt GH. Effect of HMGcoA reductase inhibitors on stroke. A meta-analysis of randomized ,controlled trials [J]. Ann Intern Med, 1998, 128: 89-95
  • 10[9]Byington RP, Jukema JW, Salonen JT, et al. Reduction IN cardiovascular events during pravastatin therapy [J]. Circulation, 1995, 92: 2 419-425

共引文献230

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部